- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00971074
Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy
February 24, 2021 updated by: Grant Jones
The Use of Viscosupplementation for the Treatment of Patients With Persistent Non-mechanical Pain Status-post Partial Menisectomy
The investigators' objective is to analyze a group of patients who have had a partial meniscectomy but continue to have knee pain after surgery with a double-blind, randomized prospective study comparing the use of Hylan G-F 20(single injection of a viscosupplementation) versus placebo injection.
The investigators would expect patients who receive the treatment (Hylan G-F 20) to have lower pain compared to the patients who were in the placebo group (had the needle injected into the knee but no medication or substance injected) since Hylan G-F 20 has been shown to decrease pain in arthritic patients.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
A great majority of patients who have a partial menisectomy for mechanical symptoms do well with full return of function without pain.
There is a sub-group of patients who are found to have Grade II- III chondromalacia lesions (deemed arthritic) at the time of surgery that have persistent generalized "arthritic-type" pain despite relief of their mechanical symptoms.
To date, there are no published studies analyzing if this treatment is better than no treatment in this group of patients.
We would expect patients who receive the treatment (Hylan G-F 20) to have lower pain compared to the patients who were in the placebo group (had the needle injected into the knee but no medication or substance injected) since Hylan G-F 20 has been shown to decrease pain in arthritic patients.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43221
- The Ohio State University Sports Medicine Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-60
- S/P partial medial and/or lateral partial meniscectomy
- Pre-operative MRI diagnosed meniscal tear
- Diffuse, non-focal arthroscopically diagnosed ICRS Grade II or III chondromalacia. (used to determine the presence of tibiofemoral osteoarthritis)
- Baseline VAS pain score between 50 and 80mm.
- Persistent, generalized knee pain without mechanical symptoms
- Kellgren/Lawrence (K/L) grade II or III (used to determine the presence of tibiofemoral osteoarthritis)
Exclusion Criteria:
- Bilateral arthroscopy (within 6 months pre- and post- initial VAS score.
- Complete meniscectomy
- Microfracture (via drilling, picking, abrading, thermal or radiofrequency or any procedure that violates the subchondral plate)
- Focal chondral lesion visualized on arthroscopy or any focal cartilage procedure (e.g. ACI, OATS, mosaicplasty, etc)
- Concomitant ligamentous injury or repair
- K/L stage I or IV
- Significant Varus or Valgus clinical malalignment
- S/P tibial osteotomy in target knee
- Isolated patello-femoral OA or isolated anterior knee pain
- Prosthetic implant in either knee
- Re-injury in time between original surgery and baseline visit
- Inflammatory arthritis (e.g. rheumatoid arthritis, gout, pseudogout (chondrocalcinosis), lupus, etc)
- Obesity with BMI > 35 (at time of initial VAS score
- NSAIDs or opiates within one week of baseline randomization or during trial period
- Known allergy to viscosupplements, known allergy to avian, egg or feather products
- Prior Viscosupplementation use in ipsilateral knee
- Oral steroids (within 4 weeks of initial VAS score)
- IA steroids in target knee within 6 months
- Significant medical co-morbidities ( e.g. malignancy, hepatic, renal, cardiac, pulmonary, gastrointestinal disease) in the judgment of the investigator
- Known hip disease
- Pregnant or nursing (at time of injection, pregnancy test at visit)
- Active infection of either lower extremity or past history of septic arthritis
- Venous or lymphatic stasis in either lower extremity
- Enrolled in clinical trial within 3 months of baseline
- Contralateral knee arthritis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hylan G-F 20
Single injection of Hylan G-F 20 into the affected knee.
|
6 ml intra-articular injection given once.
The injection takes approximately 15 seconds.
Other Names:
|
Sham Comparator: Sham Injection
A needle will be inserted through the knee capsule but no medication will be injected.
|
A needle will be inserted through the knee capsule but no medication will be injected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
VAS pain scale
Time Frame: 0, 2, 6, 12, 18, 26 weeks
|
0, 2, 6, 12, 18, 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Knee injury and Osteoarthritis Outcome Score
Time Frame: 0, 2, 6, 12, 18, 26 weeks
|
0, 2, 6, 12, 18, 26 weeks
|
SF-36® Health Survey
Time Frame: 0, 2, 6, 12, 18, 26 weeks
|
0, 2, 6, 12, 18, 26 weeks
|
Physical Examination
Time Frame: 0, 2, 6, 12, 18, 26 weeks
|
0, 2, 6, 12, 18, 26 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Grant Jones, MD, Ohio State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
September 2, 2009
First Submitted That Met QC Criteria
September 2, 2009
First Posted (Estimate)
September 3, 2009
Study Record Updates
Last Update Posted (Actual)
February 25, 2021
Last Update Submitted That Met QC Criteria
February 24, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009H0156
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthralgia
-
Victoria ShanmugamCompletedArthritis | Synovitis | Arthralgia SyndromeUnited States
-
The Center for Applied Health Sciences, LLCNatreon, Inc.Completed
-
University Hospital, LilleCompleted
-
Hospital de Clinicas de Porto AlegreUnknown
-
AHS Cancer Control AlbertaNot yet recruitingArthritis | Arthralgia
-
Uppsala UniversityCompleted
-
AHS Cancer Control AlbertaRecruitingArthritis | ArthralgiaCanada
-
Riphah International UniversityRecruiting
-
Institut des Hautes Etudes Osteopathiques de NantesNot yet recruiting
Clinical Trials on Hylan G-F 20
-
Kessler FoundationUnknown
-
Genzyme, a Sanofi CompanyCompletedOsteoarthritis, HipUnited States, Canada
-
PulsalysArtialisCompletedKnee Osteoarthritis | Intra-Articular InjectionBelgium
-
Cabrini Medical CentreGenzyme, a Sanofi CompanyUnknownOsteoarthritisAustralia
-
University of CalgaryUnknownPatellofemoral Pain SyndromeCanada
-
SanofiCompleted
-
Genzyme, a Sanofi CompanyCompletedMusculoskeletal Diseases | OsteoarthritisFrance, Germany
-
Genzyme, a Sanofi CompanyCompletedOsteoarthritisNetherlands, Germany, Italy
-
Genzyme, a Sanofi CompanyCompletedMusculoskeletal Diseases | Osteoarthritis, KneeBelgium, United Kingdom, France, Netherlands, Czech Republic, Germany
-
Genzyme, a Sanofi CompanyCompleted